Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists
Isaac A Thangasamy, Edmond M Kwan, Jiasian Teh, Niranjan Sathianathen, Omar Alghazo, Shankar Siva, Arun Azad, Declan G Murphy
BJU International | WILEY | Published : 2019
The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT). Historically, in a time when systemic therapy options were scarce, the responsibility of monitoring ADT efficacy fell squarely on urologists. As the disease progressed inevitably to the castration-resistant state, primary care would transition to medical oncologists, with urologists limited to providing interventional support for local complications on an as needed basis.